未知生产厂商
MRx-4DP0004 is a probiotic bacteria indicated in the treatment of diarrhea.
MRx-4DP0004 is a probiotic bacteria indicated in the treatment of diarrhea.
MRx-4DP0004 is an immunomodulatory therapy with anti-viral activity that simultaneously downregulates molecules associated with hyper-inflammatory responses. It reduces neutrophilic and eosinophilic infiltration in the lungs, in addition to a reduction in peribronchiolar and perivascular immunopathology without the side effects associated with immunosuppressants. A study of MRx-4DP0004 also demonstrated specifics of the biotherapeutic increasing lung D4+CD44+ cells and CD4+FoxP3+ cells, decreasing activated CD11b+ dendritic cells, and reducing pro-inflammatory cytokines and chemokines involved in neutrophil migration. MRx-4DP0004 is currently being investigated for severe asthma management, however, the specific mechanism of action is currently unknown.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
